证券代码：600252 证券简称：中恒集团 公告编号：临 2025-73 广西梧州中恒集团股份有限公司 关于控股子公司为其全资子公司融资授信进行担保 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 本次担保金额 | 1,000.00 | 重庆莱美隆宇药业有限公司 万元的综合授信额度内 | | --- | --- | --- | --- | | 担保对象 | 实际为其提供的担保余额 | 3,940.00 | 万元 | | | 是否在前期预计额度内 | 是 | □否 □不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 无 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 37,348.66 | | 对外担保总额占上市公司最近一期经审计净资产的比例（%） | 6.20 | 一、担保情况概述 （一） 担保 ...

Core Viewpoint - The successful certification of the intellectual property management system by Guangxi Shuangqian Health Industry Co., Ltd. under Zhongheng Group marks a significant advancement in the company's standardization and systematization of intellectual property management, enhancing its innovation capabilities and market competitiveness [1] Group 1 - The certification was conducted under the guidance of the Wuzhou Market Supervision Bureau and followed the requirements of the "Enterprise Intellectual Property Compliance Management System" [1] - The audit included a comprehensive review of the company's intellectual property management across all departments and processes, focusing on the completeness and appropriateness of system documents, operational effectiveness, patent management during the R&D process, and the utilization and protection of intellectual property [1] - The expert group unanimously concluded that the intellectual property management system of Shuangqian Industry meets national standards and operates in a standardized and effective manner [1] Group 2 - The certification is expected to help the company optimize resource allocation, improve innovation efficiency, strengthen brand image, and enhance market recognition while reducing infringement risks and protecting legal rights [1] - The company plans to use this certification as an opportunity to continuously improve its intellectual property management system, enhance the creation, utilization, protection, and layout of intellectual property, and promote the deep integration of intellectual property with the market and industry [1] - The ultimate goal is to make intellectual property a core driving force for the company's high-quality development [1]

Group 1 - Zhongheng Group successfully acquired a Class 1 innovative drug project for treating chronic heart failure, marking a significant addition to its cardiovascular treatment pipeline [1] - The newly introduced drug targets myocardial energy metabolism regulation, addressing unmet clinical needs in chronic heart failure treatment [1] - The acquisition aligns with Zhongheng Group's strategic focus on core disease areas and enhances synergy with existing products [1] Group 2 - Zhongheng Group has increased its R&D investment, totaling 604 million yuan from 2021 to 2024, which accounts for 5.37% of its operating income [2] - The company has initiated over 80 scientific innovation projects in the past five years, including six Class 1 innovative drug projects [2] - Notable achievements include the approval of "Sanqi Granules" for clinical trials and the successful launch of a unique injection for glioma treatment [2]

Core Viewpoint - Zhongheng Group has acquired a patented technology for a new drug to treat chronic heart failure, indicating a strategic move to enhance its product line and market competitiveness [1] Group 1: Acquisition Details - Zhongheng Group's subsidiary, Zhongheng Innovation, has purchased a drug technology for chronic heart failure for RMB 55 million [1] - The acquired drug is a Class 1 innovative chemical drug that addresses energy metabolism disorders in myocardial cells, offering a new treatment pathway [1] - There are currently no similar mechanism products available in the domestic and international markets [1] Group 2: Strategic Implications - The acquisition aligns with Zhongheng Group's strategic focus on unmet clinical needs and potential markets, particularly in cardiovascular, metabolic, and autoimmune diseases [1] - The company aims to enhance its business and product line through this acquisition, thereby increasing its market competitiveness [1] - Zhongheng Group is building a differentiated competitive advantage in cardiovascular treatment by leveraging a dual-driven model of independent R&D and strategic acquisitions [1]

Market Overview - As of August 5, the Shanghai Composite Index closed at 3617.60 points, with a change of +0.96%. The Shenzhen Component Index closed at 11106.96 points, up by +0.59%, and the ChiNext Index closed at 2343.38 points, increasing by +0.39% [1]. Trading Volume Analysis - A total of 2900 stocks saw an increase in average transaction volume, with 93 stocks experiencing a rise of over 50%. Conversely, 1651 stocks reported a decrease in average transaction volume [1]. - Notable stocks with significant increases in average transaction volume include: - Xinquan Co., Ltd. (603179) with a 227.40% increase - Shanghai Shihua Development (600748) with a 195.16% increase - Zhongheng Group (600252) with a 186.00% increase [1]. Active Stocks by Transaction Count - The stocks with the highest increase in transaction count include: - Victory Energy (001331) with a 4113.61% increase in transaction count - *ST Suwu (600200) with a 1613.63% increase - Zeyu Intelligent (301179) with a 1060.11% increase [2]. Stocks with Significant Increases in Both Volume and Count - A total of 35 stocks showed an increase of over 50% in both average transaction volume and transaction count. Notable mentions include: - Chunhui Intelligent Control (300943) with a 127.35% increase in average transaction volume and a 225.19% increase in transaction count - Ningbo Port (601018) with a 106.91% increase in average transaction volume and a 56.51% increase in transaction count [4].

Market Overview - A total of 70 stocks hit the daily limit up in the A-share market, with 53 stocks hitting the limit after excluding 17 ST stocks, resulting in an overall limit-up rate of 78.65% [1] Top Performers - Zhongheng Group had the highest limit-up order volume at 513,300 hands, followed by Ma Steel, Zhongtai Automobile, and Shandong Molong with order volumes of 304,400 hands, 272,100 hands, and 245,600 hands respectively [2] - Zhongheng Group announced that its wholly-owned subsidiary plans to acquire a patent for a drug technology (LZ-01) for treating chronic heart failure, which shows significant therapeutic advantages [2] Continuous Limit-Up Stocks - *ST Yazhen achieved 5 consecutive limit-ups, while Beijiajie and Wenke Co. had 4 consecutive limit-ups. Several other stocks, including *ST Yanshi and *ST Yushun, recorded 3 consecutive limit-ups [2] Sector Highlights Robotics - Multiple stocks in the robotics sector hit the limit-up, including Dongjie Intelligent, Furi Electronics, Guoji Precision, and others. Dongjie Intelligent is focusing on industrial intelligent logistics robots to create smart factories [4][7] eSIM Technology - Stocks such as Rihai Intelligent, Dongxin Peace, and Chengtian Weiye saw limit-ups, with Rihai Intelligent's SIM7070 series NB-IoT module being highlighted for its eSIM remote management capabilities [4][5][6] Pharmaceuticals - Pharmaceutical stocks like Chengyi Pharmaceutical, Zhongheng Group, Kehua Bio, and Guilin Sanjin also hit the limit-up. Chengyi Pharmaceutical's products have won bids in multiple provincial administrative regions [9] Institutional and Retail Activity - The net selling of Shanhai Intelligent exceeded 100 million yuan, while Dongxin Peace, Innovation Medical, and Aerospace Science and Technology were the top net buying stocks [10][11] - Institutional net buying was led by Dongjie Intelligent, Xinhan New Materials, and Beifang Changlong, with amounts of 209 million yuan, 84.8 million yuan, and 52 million yuan respectively [12] ETF Performance - The Food and Beverage ETF saw a slight decline of 0.52% over the past five days, with a net inflow of 10.56 million yuan [16] - The Gaming ETF increased by 3.12%, with a net inflow of 290 million yuan [16] - The Cloud Computing 50 ETF experienced a minor decline of 0.15%, with a net outflow of 1.24 million yuan [17]

Group 1 - Niuwei Co., Ltd. reported a net profit of 637 million yuan for the first half of 2025, representing a year-on-year increase of 30.47% [1] - The company achieved a total operating revenue of 3.404 billion yuan, up 19.96% year-on-year [1] - Niuwei specializes in the research, manufacturing, and sales of industrial valves [2] Group 2 - Shandong Haohua plans to acquire a 29% stake in Zhongyan Alkali Industry with a total investment of 2.32 billion yuan [2] - The company is involved in the production of soda ash and caustic soda [3] Group 3 - Dongfang Co., Ltd. announced a partnership with Dongfang Import and Export Company to develop overseas marketing business [38] - The company focuses on the research, production, and sales of light commercial vehicles and powertrains [38] Group 4 - Xinyuan Technology reported a net profit of 52.6 million yuan for the first half of 2025, a year-on-year increase of 10.70% [12] - The company achieved an operating revenue of 2.871 billion yuan, up 3.86% year-on-year [12] - Xinyuan provides one-stop custom development and production services for pharmaceutical companies and research institutions [12] Group 5 - Zhuhai Piano announced that its subsidiary won the operating rights project for the Baihuazhai scenic area, with an investment of no less than 400 million yuan over 20 years [21] - The company specializes in the research, manufacturing, and sales of pianos and digital musical instruments [21] Group 6 - Zhenghong Technology reported a sales revenue of 26.02 million yuan from pig sales in July, a year-on-year increase of 288.69% [16] - The company sold 63,000 pigs in total from January to July 2025, with a cumulative sales revenue of 109 million yuan, representing a year-on-year increase of 38.06% [16] - Zhenghong focuses on feed products and pig farming [17] Group 7 - ST Nuotai received the cGMP certification from Brazil's National Health Surveillance Agency for its production facility [15] - The company specializes in the research and development of peptide drugs and small molecule pharmaceuticals [15] Group 8 - Guizhou Moutai has repurchased a total of 3.4517 million shares, accounting for 0.2748% of its total share capital, with a total expenditure of 5.301 billion yuan [48][49] - The company is engaged in the production and sales of Moutai liquor and related products [49]

Group 1 - The Helicobacter pylori concept sector declined by 0.50%, ranking among the top declines in concept sectors, with notable declines in stocks such as Keta Bio, Anglikang, and Asia-Pacific Pharmaceutical [1][2] - Among the 49 stocks in the Helicobacter pylori concept sector, 27 stocks saw price increases, with Zhongheng Group, Hanyu Pharmaceutical, and *ST Sansheng leading the gains at 9.85%, 5.63%, and 5.05% respectively [1][4] - The Helicobacter pylori concept sector experienced a net outflow of 1.725 billion yuan in main funds, with Hanyu Pharmaceutical seeing the largest outflow of 909.33 million yuan [2][3] Group 2 - The top gainers in the concept sectors included the Armament Reorganization concept at 6.12%, PEEK materials at 4.11%, and Brain-Computer Interface at 2.72% [2] - The main funds saw inflows in stocks such as Zhongheng Group, Baicheng Pharmaceutical, and Asia Treasure Pharmaceutical, with inflows of 88.23 million yuan, 63.86 million yuan, and 19.51 million yuan respectively [2][4] - The stocks with the largest net outflows in the Helicobacter pylori concept included Asia-Pacific Pharmaceutical at -8.16%, Keta Bio at -10.28%, and Anglikang at -9.46% [2][3]

Market Performance - As of August 5, the generic drug consistency evaluation concept declined by 0.55%, ranking among the top declines in the concept sector [1] - Within the sector, notable declines were seen in companies such as Angli Kang, Asia-Pacific Pharmaceutical, and Nanxin Pharmaceutical, while 46 stocks experienced price increases, with Chengyi Pharmaceutical, Guilin Sanjin, and Zhongheng Group leading with increases of 10.04%, 10.00%, and 9.85% respectively [1] Capital Flow - The generic drug consistency evaluation sector saw a net outflow of 3.403 billion yuan, with 112 stocks experiencing net outflows, and 5 stocks seeing outflows exceeding 100 million yuan [2] - The stock with the highest net outflow was Hanyu Pharmaceutical, with a net outflow of 909.3 million yuan, followed by Asia-Pacific Pharmaceutical, Guangsheng Tang, and Yipinhong with net outflows of 192.45 million yuan, 135.13 million yuan, and 119.26 million yuan respectively [2] Top Gainers and Losers - The top gainers in the sector included Chengyi Pharmaceutical, Guilin Sanjin, and Zhongheng Group, with respective net inflows of 102 million yuan, 94.85 million yuan, and 88.22 million yuan [6] - Conversely, the top losers included Hanyu Pharmaceutical, Asia-Pacific Pharmaceutical, and Guangsheng Tang, with significant net outflows [2][3]

| 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002275 | 桂林三金 | 9927.28万 | 23.81% | -5811.71万 | -13.94% | -4115.57万 | -9.87% | | 600252 | 中恒集团 | 6998.27万 | 48.21% | -3381.31万 | -23.29% | -3616.96万 | -24.92% | | 002873 | 新天药业 | 2543.66万 | 4.72% | 1806.11万 | 3.35% | -4349.77万 | -8.06% | | 000623 | 吉林敖东 | 1889.04万 | 6.29% | -1961.54万 | -6.53% | 72.50万 | 0.24% | | 000423 | 东阿阿胶 | 1276.81万 | 5.66% | -797.15万 | -3.53% | -479.66万 | -2.13% | ...